Disease Domain | Count |
---|---|
Nervous System Diseases | 1 |
Neoplasms | 1 |
Immune System Diseases | 1 |
Hemic and Lymphatic Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 1 |
Enzyme | 1 |
Target |
Mechanism ALK inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. JP |
First Approval Date04 Jul 2014 |
Target |
Mechanism DNase I stimulants |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date30 Dec 1993 |
Start Date17 Aug 2021 |
Sponsor / Collaborator |
Start Date01 Jan 2012 |
Sponsor / Collaborator |
Start Date02 Feb 2009 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Alectinib Hydrochloride ( ALK x RET ) | Non-Small Cell Lung Cancer More | Approved |
Dornase Alfa ( DNase I ) | Cystic Fibrosis More | Approved |